CD8A and Alzheimer disease: It is crucial to identify the specific CD8+ T cell subtype(s) present in the brain and understand their rejuvenation potential when contemplating repurposing anti-PD-1 antibodies, originally designed for anticancer purposes, for the treatment of AD.